用特征选择和数据平衡方法对阿尔茨海默氏症疾病分类进行有效的可解释模型,采用集体学习方法
Yogita Dubey1, Aditya Bhongade1, Prachi Palsodkar2
1Department of Electronics and Telecommunication, Yeshwantrao Chavan College of Engineering, Nagpur 441110, India.
Diagnostics (Basel, Switzerland)
|January 8, 2025
概括
这项研究引入了用于早期阿尔茨海默病诊断的机器学习框架,达到95%的准确性. 可解释模型通过突出关键诊断特征来帮助临床医生,改善患者管理.
科学领域:
- 神经科学是一个神经科学.
- 人工智能的人工智能
- 医疗信息学 医疗信息学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,也是痴呆的主要原因.
- 早期AD诊断至关重要,但由于疾病的复杂性而具有挑战性.
- 临床数据对于AD分类至关重要,但面临着数据不平衡和高维度等障碍.
研究的目的:
- 提出一个计算效率高,可靠和透明的机器学习 (ML) 框架,用于AD患者的分类.
- 为了提高医疗从业人员对模型的解释性,以了解复杂的患者模式.
- 开发一个系统,以帮助早期和准确诊断阿尔茨海默病.
主要方法:
- 采用集体学习 (增强算法) 来提高分类准确性.
- 利用随机抽样进行数据平衡和特征选择/减少进行模型优化.
- 综合可解释AI (XAI) 工具 (SHAP,LIME,ALE,ELI5) 提供模型透明度和功能重要性见解.
主要成果:
- 实现了强大,可解释和临床相关的AD诊断框架.
- 拟议的ML方法在对阿尔茨海默病患者进行分类时表现出高达95%的高准确性.
- 该框架有效地确定了影响分类的关键临床特征,提高了诊断可靠性.
结论:
- 整合合体学习与XAI以及平衡的特征选择数据显著提高了AD分类的准确性和可解释性.
- 这种方法为阿尔茨海默病的早期和明智的临床决策提供了有希望的工具.
- 开发的框架提供了透明度,使临床医生能够信任和理解AD的预测因素.
相关概念视频
Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444
Alzheimer's Disease: Treatment
161
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
161


